CORRECTING & REPLACING ImmunoGen, Inc. Announces Preclinical Findings for IMGN779, a Potential Treatment for Acute Myeloid Le...
June 16 2014 - 9:14AM
Business Wire
- Novel antibody-drug conjugate is
designed to selectively target and kill CD33-expressing acute
myeloid leukemia cells, including leukemic stem cells, while
sparing normal cells.
- IMGN779 utilizes one of the Company’s
new DNA-acting payload agents, DGN462.
- ImmunoGen is on track to submit an IND
for IMGN779 in 2015.
Reissuing release to add ticker symbol for searching
purposes.
The corrected release reads:
IMMUNOGEN, INC. ANNOUNCES PRECLINICAL FINDINGS FOR IMGN779, A
POTENTIAL TREATMENT FOR ACUTE MYELOID LEUKEMIA
- Novel antibody-drug conjugate is
designed to selectively target and kill CD33-expressing acute
myeloid leukemia cells, including leukemic stem cells, while
sparing normal cells.
- IMGN779 utilizes one of the Company’s
new DNA-acting payload agents, DGN462.
- ImmunoGen is on track to submit an IND
for IMGN779 in 2015.
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that
develops novel anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, disclosed for the first time
preclinical data for IMGN779. The data were presented at the 19th
Congress of the European Hematology Association (EHA) meeting in
Milan, Italy (abstract# P802). IMGN779 is a novel, CD33-targeting,
DNA-alkylating ADC that is a potential treatment for acute myeloid
leukemia (AML).
“Despite good initial responses to existing therapies, many AML
patients relapse, driving the need for new treatment options,”
commented Dr. Charles Morris, Executive Vice President and Chief
Development Officer. “We believe the unique profile of IMGN779 will
enable the achievement of desired activity with a better
tolerability profile than other agents currently used to treat this
disease.”
IMGN779 is an ADC designed to selectively target and kill AML
cells, including leukemic stem cells, while sparing normal cells.
IMGN779 utilizes DGN462, one of the Company’s new DNA-acting
payload agents.
In preclinical findings reported at EHA, IMGN779 demonstrated
potent, targeted activity against primary AML patient cells in
vitro. IMGN779 can selectively kill leukemic cells (blasts) while
sparing normal hematopoietic (blood) stem cells. IMGN779 was found
to be highly active against human AML xenografts in vivo,
demonstrating potent and targeted activity. IMGN779 was well
tolerated without delayed toxicity in animal models.
IMGN779 is on track to become the Company’s next wholly owned
clinical-stage compound. ImmunoGen is preparing to submit the
IMGN779 IND in mid-2015.
About IMGN779
IMGN779 is a novel, DNA-alkylating ADC. Its payload, linker and
antibody were developed by ImmunoGen and are wholly owned by the
Company. IMGN779 comprises the highly potent, DNA-alkylating
payload DGN462 conjugated via cleavable disulfide linker to the
CD33-targeting antibody, Z4681A.
About ImmunoGen’s DNA-acting Payload Agents
Created by ImmunoGen scientists, the IGN family of DNA-acting
payload agents, including DGN462, are designed to effectively
alkylate DNA, while avoiding the delayed toxicity that can develop
with agents that cross-link DNA in addition to alkylating it.1
ImmunoGen developed its IGN family of DNA-acting payload agents to
complement its successful family of tubulin-acting agents (e.g.,
DM1, DM4), as some cancers respond more to DNA-acting agents than
to tubulin-acting agents.1,2
The Company began by developing DNA-acting agents with both
DNA-crosslinking and -alkylating properties. However, ImmunoGen
scientists identified that such agents were associated with
significant delayed toxicity. To achieve the dual objective of
efficacy and tolerability with this platform, ImmunoGen developed
more advanced IGN agents which are DNA-alkylators only. These IGN
payload agents retain high potency, but avoid delayed toxicity.
About AML
Acute myeloid leukemia (AML) is a hematologic malignancy that
starts in the bone marrow where different types of new blood cells
are made. In the US in 2014, more than 18,000 adults will be newly
diagnosed with AML and more than 10,000 will die from the
disease.3
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells; the
Company has also developed antibodies with anticancer activity of
their own. The first product with ImmunoGen’s ADC technology is
Roche’s Kadcyla®. ImmunoGen has three wholly owned product
candidates in clinical testing with additional compounds in
clinical testing through the Company’s partnerships with Amgen,
Bayer HealthCare, Biotest and Sanofi. More information about
ImmunoGen can be found at www.immunogen.com.
1 Miller et al., AACR-NCI-EORTC 2013, abstract #C160.
2 Whiteman et al., AACR-NCI-EORTC 2013, abstract #C162.
3 American Cancer Society (2014), Leukemia: Acute Myeloid
Detailed Guide.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including IMGN779, including risks
related to preclinical and clinical studies, their timings and
results. A review of these risks can be found in ImmunoGen’s Annual
Report on Form 10-K for the fiscal year ended June 30, 2013 and
other reports filed with the Securities and Exchange
Commission.
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024